Insider Selling: Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Sells 37,967 Shares of Stock

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 37,967 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $69.15, for a total value of $2,625,418.05. Following the completion of the sale, the chief executive officer now owns 2,116,160 shares in the company, valued at $146,332,464. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

  • On Thursday, October 10th, Christopher Richard Anzalone sold 56,325 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $31.83, for a total value of $1,792,824.75.
  • On Friday, September 20th, Christopher Richard Anzalone sold 4,250 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $29.00, for a total value of $123,250.00.
  • On Tuesday, September 24th, Christopher Richard Anzalone sold 66,645 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $28.20, for a total value of $1,879,389.00.

Shares of NASDAQ:ARWR opened at $67.27 on Friday. The firm has a market capitalization of $6.44 billion, a P/E ratio of 97.49 and a beta of 1.98. The stock has a 50 day moving average price of $48.38 and a 200-day moving average price of $33.56. Arrowhead Pharmaceuticals Inc has a 52-week low of $10.41 and a 52-week high of $73.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.03). The firm had revenue of $43.29 million for the quarter, compared to the consensus estimate of $36.97 million. Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. On average, analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.29 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 96.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 500 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $34,000. Mascoma Wealth Management LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $46,000. Pearl River Capital LLC purchased a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at about $111,000. Finally, Riverhead Capital Management LLC purchased a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at about $148,000. Institutional investors and hedge funds own 68.75% of the company’s stock.

Several research firms recently weighed in on ARWR. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 9th. ValuEngine cut shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $81.00 target price (up from $45.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, November 29th. B. Riley reaffirmed a “buy” rating and set a $83.00 target price (up previously from $59.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 27th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 price target (up previously from $24.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 19th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals currently has an average rating of “Buy” and an average price target of $71.20.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

See Also: What does it mean to hold a stock in street name?

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit